S. Agresta

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results

C. L. Vogel, Howard A. Burris, Steven Limentani et al. · Journal of Clinical Oncology · 2009 · 63 citations

Medicine, Oncology, Pharmacology +17

A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.

Ian E. Krop, Patricia LoRusso, Kathy D. Miller et al. · Cancer Research · 2009 · 46 citations

Medicine, Oncology, Pharmacology +17

Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas

C. E. Vigil, Alberto Chiappori, C. A. Williams et al. · Journal of Clinical Oncology · 2008 · 16 citations

Medicine, Oncology, Pharmacology +17

A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.

M. J. Higgins, N. Gabrail, K. Miller et al. · Journal of Clinical Oncology · 2011 · 16 citations

Life Sciences, Medicinal Chemistry, Pharmacology +16

Sunitinib treatment of pediatric metastatic GIST after failure of imatinib

Katherine A. Janeway, Don Matthews, James E. Butrynski et al. · Journal of Clinical Oncology · 2006 · 14 citations

Medicine, Oncology, Pharmacotherapy +15